FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mihaela Mocanu

Research Profile

Disorders

Living Beings

Procedures

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Derek Hausenloy; Mihaela M Mocanu; Abigail M Wynne; Derek M Yellon
Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart.
Hannah J Whittington; Derek M Yellon; Andrew R Hall; Derek J Hausenloy; Catarina P McLaughlin; Mihaela M Mocanu
Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon.
Hilary K Siddall; Derek M Yellon; Plamena R Angelova; Niall Burke; Sean M Davidson; Emma Deas; Andrew R Hall; Marthe H R Ludtmann; Mihaela M Mocanu; Uma A Mukherjee; Sang-Bing Ong; Derek J Hausenloy
Loss of PINK1 Increases the Heart's Vulnerability to Ischemia-Reperfusion Injury.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mihaela Mocanu (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Derek Hausenloy; Mihaela M Mocanu; Abigail M Wynne; Derek M Yellon
Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart.
Journal of cardiovascular pharmacology and therapeutics 2013;18(3):263-9.
2013: Hannah J Whittington; Derek M Yellon; Andrew R Hall; Derek J Hausenloy; Catarina P McLaughlin; Mihaela M Mocanu
Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2013;27(1):5-16.
2013: Hilary K Siddall; Derek M Yellon; Plamena R Angelova; Niall Burke; Sean M Davidson; Emma Deas; Andrew R Hall; Marthe H R Ludtmann; Mihaela M Mocanu; Uma A Mukherjee; Sang-Bing Ong; Derek J Hausenloy
Loss of PINK1 Increases the Heart's Vulnerability to Ischemia-Reperfusion Injury.
PloS one 2013;8(4):e62400.
2012: Suma P Kunuthur; Mihaela M Mocanu; Derek J Hausenloy; Brian A Hemmings; Derek M Yellon
The Akt1 isoform is an essential mediator of ischaemic preconditioning.
Journal of cellular and molecular medicine 2012;16(8):1739-49.
2012: Hannah J Whittington; Derek M Yellon; Girish G Babu; Mihaela M Mocanu; Derek J Hausenloy
The diabetic heart: too sweet for its own good?
Cardiology research and practice 2012;2012():845698.
2011: Marta A Paiva; Zoe Rutter-Locher; Lino M Gonçalves; Luís A Providência; Sean Davidson; Derek M Yellon; Mihaela M Mocanu
Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury.
American journal of physiology. Heart and circulatory physiology 2011;300(6):H2123-34.
2011: Robert M Bell; Mihaela M Mocanu; Derek M Yellon
Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion.
Journal of molecular and cellular cardiology 2011;50(6):940-50.
2011: Christopher C T Smith; Shiang Y Lim; Abigail M Wynne; Vivek Sivaraman; Sean Davidson; Mihaela M Mocanu; Derek Hausenloy; Derek M Yellon
Failure of the adipocytokine, resistin, to protect the heart from ischemia-reperfusion injury.
Journal of cardiovascular pharmacology and therapeutics 2011;16(1):63-71.
2010: Derek Hausenloy; Gary Baxter; Robert Bell; Hans Erik Bøtker; Sean Davidson; James Downey; Gerd Heusch; Masafumi Kitakaze; Sandrine Lecour; Robert M Mentzer; Mihaela M Mocanu; Michel Ovize; Rainer Schulz; Richard Shannon; Malcolm Walker; Gail Walkinshaw; Derek M Yellon
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations.
Basic research in cardiology 2010;105(6):677-86.
2010: Marta A Paiva; Lino M Gonçalves; Luis A Providência; Sean Davidson; Derek M Yellon; Mihaela M Mocanu
Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2010;24(1):25-32.
2009: Marta Paiva; Niels P Riksen; Sean Davidson; Derek Hausenloy; Pedro Monteiro; Lino Gonçalves; Luís Providência; Gerard A Rongen; Paul Smits; Mihaela M Mocanu; Derek M Yellon
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.
Journal of cardiovascular pharmacology 2009;53(5):373-8.
2009: Mihaela M Mocanu; Derek M Yellon
Letter to the editor: "Zinc and cardioprotection: the missing link".
American journal of physiology. Heart and circulatory physiology 2009;296(1):H233-4; author reply H235.
2008: Hilary K Siddall; Clare E Warrell; Sean Davidson; Mihaela M Mocanu; Derek M Yellon
Mitochondrial PINK1--a novel cardioprotective kinase?
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2008;22(6):507-8.
2008: Hilary K Siddall; Clare E Warrell; Derek M Yellon; Mihaela M Mocanu
Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency.
Basic research in cardiology 2008;103(6):560-8.
2008: Gurpreet S Bhamra; Derek Hausenloy; Sean Davidson; Richard D Carr; Marta Paiva; Abigail M Wynne; Mihaela M Mocanu; Derek M Yellon
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening.
Basic research in cardiology 2008;103(3):274-84.
2008: N R Mudalagiri; Mihaela M Mocanu; C Di Salvo; Shyam Kolvekar; M Hayward; J Yap; B Keogh; Derek M Yellon
Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation.
British journal of pharmacology 2008;153(1):50-6.
2007: Shiang Y Lim; Sean Davidson; Mihaela M Mocanu; Derek M Yellon; Christopher C T Smith
The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2007;21(6):467-9.
2007: Christopher C T Smith; Mihaela M Mocanu; Jonathan Bowen; Abigail M Wynne; James C Simpkin; Richard A Dixon; Michael B Cooper; Derek M Yellon
Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2007;21(6):409-14.
2007: Mihaela M Mocanu; Padmanabhan Shakkottai; Derek M Yellon
The power of drug co-administration: smaller doses better outcomes.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2007;21(5):319-20.
2007: Amal K Bose; Mihaela M Mocanu; Richard D Carr; Derek M Yellon
Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2007;21(4):253-6.
2006: Christopher C T Smith; Mihaela M Mocanu; Sean Davidson; Abigail M Wynne; James C Simpkin; Derek M Yellon
Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects.
British journal of pharmacology 2006;149(1):5-13.
2006: Derek Hausenloy; Mihaela M Mocanu; Derek M Yellon
Is this truly ischemic preconditioning?
Circulation research 2006;99(4):e11.
2006: Mihaela M Mocanu; Duncan C Field; Derek M Yellon
A potential role for PTEN in the diabetic heart.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2006;20(4):319-21.
2005: Abigail M Wynne; Mihaela M Mocanu; Derek M Yellon
Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK.
Journal of cardiovascular pharmacology 2005;46(6):817-22.
2005: Andrew Tsang; Derek Hausenloy; Mihaela M Mocanu; Richard D Carr; Derek M Yellon
Preconditioning the diabetic heart: the importance of Akt phosphorylation.
Diabetes 2005;54(8):2360-4.
2005: Kwabena Mensah; Mihaela M Mocanu; Derek M Yellon
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?
Journal of the American College of Cardiology 2005;45(8):1287-91.
2005: Christopher A Efthymiou; Mihaela M Mocanu; Derek M Yellon
Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling.
Journal of cardiovascular pharmacology 2005;45(3):247-52.
2005: Derek Hausenloy; Andrew Tsang; Mihaela M Mocanu; Derek M Yellon
Ischemic preconditioning protects by activating prosurvival kinases at reperfusion.
American journal of physiology. Heart and circulatory physiology 2005;288(2):H971-6.
2005: Amal K Bose; Mihaela M Mocanu; Richard D Carr; Derek M Yellon
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2005;19(1):9-11.
2005: Amal K Bose; Mihaela M Mocanu; Richard D Carr; Christian L Brand; Derek M Yellon
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Diabetes 2005;54(1):146-51.
2004: Christopher A Efthymiou; Mihaela M Mocanu; Jackie de Belleroche; Dominic J Wells; David S Latchmann; Derek M Yellon
Heat shock protein 27 protects the heart against myocardial infarction.
Basic research in cardiology 2004;99(6):392-4.
2004: Andrew Tsang; Derek Hausenloy; Mihaela M Mocanu; Derek M Yellon
Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway.
Circulation research 2004;95(3):230-2.
2004: Derek Hausenloy; Mihaela M Mocanu; Derek M Yellon
Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning.
Cardiovascular research 2004;63(2):305-12.
2003: Mihaela M Mocanu; Derek M Yellon
p53 down-regulation: a new molecular mechanism involved in ischaemic preconditioning.
FEBS letters 2003;555(2):302-6.
2002: Helen L Maddock; Mihaela M Mocanu; Derek M Yellon
Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury.
American journal of physiology. Heart and circulatory physiology 2002;283(4):H1307-13.
2002: Mihaela M Mocanu; Robert M Bell; Derek M Yellon
PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning.
Journal of molecular and cellular cardiology 2002;34(6):661-8.
2001: Gary F Baxter; Mihaela M Mocanu; Bhawanjit K Brar; D S Latchman; D M Yellon
Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK.
Journal of cardiovascular pharmacology 2001;38(6):930-9.
2001: Mihaela M Mocanu; Helen L Maddock; Gary F Baxter; Chris L Lawrence; Nicholas B Standen; Derek M Yellon
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.
Circulation 2001;103(25):3111-6.
2000: Mihaela M Mocanu; Gary F Baxter; Y Yue; S D Critz; Derek M Yellon
The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical.
Basic research in cardiology 2000;95(6):472-8.
2000: Mihaela M Mocanu; Gary F Baxter; D M Yellon
Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury.
British journal of pharmacology 2000;130(2):197-200.
1999: Mihaela M Mocanu; S Gadgil; Derek M Yellon; Gary F Baxter
Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1999;13(2):115-22.
1997: Gary F Baxter; Mihaela M Mocanu; Derek M Yellon
Attenuation of myocardial ischaemic injury 24 h after diacylglycerol treatment in vivo.
Journal of molecular and cellular cardiology 1997;29(7):1967-75.
1994: M E Speechly-Dick; Mihaela M Mocanu; Derek M Yellon
Protein kinase C. Its role in ischemic preconditioning in the rat.
Circulation research 1994;75(3):586-90.